"Biotech*," the Growth Wing of Pharma

Didn't know that? The Chinese certainly do

Look for us on your shores... and in your medicine cabinets.





Some headlines and paragraphs spelling it out









Money is rushing into biotech at breakneck speed this year, and one part of the globe is accounting for much of the uptick: China.

VC deals were teeming with Chinese investors in the first half of the year, with China-based firms participating in US biotech investment rounds worth $5.1 billion, according to data from PitchBook. For some perspective, that beats 2017's total figure of $4 billion — and we're only six months into the year. ENDPOINTS NEWS**







Chinese funds participated in investment rounds in US biotech companies worth $5.1bn in the first half of this year, beating the $4bn in 2017, the first year of large Chinese inflows into the sector, according to PitchBook. →

Financial Times 🔐





Shanghai Pharmaceuticals on the prowl for acquisitions in US and Europe